Centrum Medyczne Oporow — Clinical Trial Site

81 Registered trials

34 Currently recruiting

Organisation

Centrum Medyczne Oporow

Location

Wroclaw, Poland

Identifier

ORG-100043338

Address

Ul. Ul. Ludwika Solskiego 4a/1, 52-416, Poland

Departments

#40043: Rheumatology
#PL10012: Gastrology
1913
3025:Cardiology
3552: NA
3552: Rumatologia
40043: Centrum Medyczne Oporow
Centrum Medyczne Oporów
Dermatology
Dermatology Department
Gastroenterology
Medical Centre Oporow
n/a
na
not applicable/nie dotyczy
PL10002: Gastroneterology
PL10023: Gastroenterologia
PL10034: Gastroenterologia
Rheumatology

Clinical trials at this site (81)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending

2025-524640-35-00 Ulcerative colitis (Inflammatory Bowel Disease) 4
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Recruiting

2025-521038-27-00 Immune system diseases 5 2026-06-23
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting

2025-521590-13-00 Moderately to Severely Active Crohn’s Disease 5 2026-05-28
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting

2025-522001-38-00 Crohn’s Disease 4 2026-05-27
A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting

2025-522702-21-00 Ulcerative Colitis is a type of inflammatory bowel dise 4 2026-01-26
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting

2023-503545-67-00 Tourette's Disorder 5 2024-04-30
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting

2022-500718-24-00 IgG4-Related Disease 5 2023-06-09
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Recruiting

2022-500700-22-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-25
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27